Wall Street Journal (07/16/12) Wang, Shirley S.
Drug makers, including Eli Lilly, Pfizer and Johnson & Johnson, have spent hundreds of millions of dollars pursuing what could be the first treatments to address the underlying mechanism of Alzheimer's disease. Soon they'll know whether those bets have paid off and they have the industry's next blockbusters. Anticipation is running high for late-stage trial results on the compounds furthest along in development. Pfizer, Johnson & Johnson and their partner Elan are expected to report first, issuing initial findings as early as next month for their drug bapineuzumab. Lilly is expected to reveal this fall how its experimental therapy solanezumab fared.